Abstract: Provided is a method for preparing islatravir, including: 1) subjecting compound of Formula II as a raw material to selective hydroxyl protection reaction to obtain compound of Formula III, 2) subjecting the compound of Formula III to hydroxyl oxidation reaction to obtain compound of Formula IV; 3) subjecting the compound of Formula IV and dimethyl diazomethylphosphonate to reaction under an alkaline condition to obtain compound of Formula V; 4) subjecting the compound of Formula V to protecting group conversion reaction to obtain compound of Formula VI; 5) subjecting the compound of Formula VI to glycosylation reaction to obtain compound of Formula VII; 6) subjecting the compound of Formula VII to selective deprotection reaction to obtain compound of Formula VIII; 7) subjecting the compound of Formula VIII to deoxidation reaction to obtain compound of Formula IX; and 8) subjecting the compound of Formula IX to debenzylation reaction to obtain the islatravir.

Abstract: The present invention provides an anti-PD-L1/anti-CD47 bispecific antibody and a preparation method therefor. The antibody has characteristics of a natural IgG, and is a highly stable heterodimeric form without heavy and light chain mismatching. The bispecific antibody can bind two target molecules at the same time and has a smaller side effect.

Abstract: The present disclosure provides a preparation method of a 2?-substituted pyrimidine nucleoside, including the following steps: subjecting a compound of Formula I or Formula II to a series of process including dehydration, selective 5?-protection, ring-opening reaction using magnesium alkoxide and deprotection to obtain a 2?-substituted pyrimidine nucleoside of Formula VII or Formula VIII. In the present disclosure, the preparation method has desirable universality for different substrates; the ring-opening with a protected anhydrous pyrimidine nucleoside improves a solubility of the substrate, with milder reaction conditions than those of a traditional synthetic route; the formation of a dimer is avoided during the ring-opening to improve the yield; in addition, an intermediate (5?-O-bis-p-methoxytrityl-protected 2?-substituted pyrimidine nucleoside) can be directly used in synthesis of a corresponding phosphoramidite monomer, with a wider potential for use.

Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.

Abstract: An antibody specifically binding to IL-17A or a functional fragment thereof. The antibody or functional fragment thereof includes an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and a functional fragment thereof.

Abstract: Disclosed is a high-voltage shielded connector assembly. The technical problem to be solved is that existing high-voltage connectors are large in volume, complex to assemble and machine, non-universal, and high in cost. The present invention comprises a socket protection sleeve body, a pin, a socket shielding layer fixed on the socket protection sleeve body and a fixing clip fixing the socket shielding layer, wherein the pin cooperates with the socket protection sleeve body; and the pin comprises a two-layer locking structure formed by a main locking structure and an auxiliary locking structure. After using the above-mentioned technical solution, the present invention uses a high-voltage large-current plate-end shielded connector which is made of plastic and is suitable for new energy automobiles, is low in cost, has high production efficiency, is small in volume, and is simple in wiring harness assembly and processing.

Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.

Abstract: Disclosed is a high-voltage shielded connector assembly. The technical problem to be solved is that existing high-voltage connectors are large in volume, complex to assemble and machine, non-universal, and high in cost. The present invention comprises a socket protection sleeve body, a pin, a socket shielding layer fixed on the socket protection sleeve body and a fixing clip fixing the socket shielding layer, wherein the pin cooperates with the socket protection sleeve body; and the pin comprises a two-layer locking structure formed by a main locking structure and an auxiliary locking structure. After using the above-mentioned technical solution, the present invention uses a high-voltage large-current plate-end shielded connector which is made of plastic and is suitable for new energy automobiles, is low in cost, has high production efficiency, is small in volume, and is simple in wiring harness assembly and processing.

Abstract: An antibody specifically binding to IL-17A or a functional fragment thereof. The antibody or functional fragment thereof includes an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and a functional fragment thereof.